BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16303829)

  • 1. Commentary: the PROactive study--the glass is half full.
    Fonseca V; Jawa A; Asnani S
    J Clin Endocrinol Metab; 2006 Jan; 91(1):25-7. PubMed ID: 16303829
    [No Abstract]   [Full Text] [Related]  

  • 2. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
    Szymborska-Kajanek A; Strojek K
    Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
    [No Abstract]   [Full Text] [Related]  

  • 3. [Glitazones critically evaluated].
    Schernthaner G
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
    [No Abstract]   [Full Text] [Related]  

  • 4. [The effects of thiazolidinedione from the cardiologic viewpoint].
    Ziegler R
    Med Monatsschr Pharm; 2005 Oct; 28(10):365. PubMed ID: 16245456
    [No Abstract]   [Full Text] [Related]  

  • 5. The PROactive study: some answers, many questions.
    Yki-Järvinen H
    Lancet; 2005 Oct; 366(9493):1241-2. PubMed ID: 16214581
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
    MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787
    [No Abstract]   [Full Text] [Related]  

  • 7. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinediones.
    Yki-Järvinen H
    N Engl J Med; 2004 Sep; 351(11):1106-18. PubMed ID: 15356308
    [No Abstract]   [Full Text] [Related]  

  • 9. The Avandia debate: an unhappy conclusion.
    Bloomgarden Z; Handelsman Y
    J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
    [No Abstract]   [Full Text] [Related]  

  • 10. Implications of thiazolidinedione use and cardiovascular risk: is it all about the sugar?
    Krantz MJ
    Pharmacotherapy; 2006 Jul; 26(7):1049; discussion 1049-50. PubMed ID: 16803430
    [No Abstract]   [Full Text] [Related]  

  • 11. PROactive in patients with type 2 diabetes and previous myocardial infarction: swinging the sword of Damocles?
    Westerbacka J
    J Am Coll Cardiol; 2007 May; 49(17):1781-2. PubMed ID: 17466228
    [No Abstract]   [Full Text] [Related]  

  • 12. [Too positive comment on glitazones].
    Lindberg M
    Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
    [No Abstract]   [Full Text] [Related]  

  • 13. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
    Holleman F; Gerdes VE; de Vries JH; Hoekstra JB
    Ned Tijdschr Geneeskd; 2006 Feb; 150(7):358-60. PubMed ID: 16523797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
    Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888
    [No Abstract]   [Full Text] [Related]  

  • 15. [Warning signals insulin resistance. Insulin resistance causes not only diabetes].
    MMW Fortschr Med; 2004 Jul; 146(29-30):49. PubMed ID: 15540564
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular effects of thiazolidinediones: a review of the literature.
    Acharya D; Falik R
    South Med J; 2009 Jan; 102(1):51-6. PubMed ID: 19077768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Glitazones more than hypoglycemics in type 2 diabetes].
    Sjöholm A
    Lakartidningen; 2007 Oct 24-30; 104(43):3201-3. PubMed ID: 18018938
    [No Abstract]   [Full Text] [Related]  

  • 18. PROactive study.
    Guillausseau PJ
    Lancet; 2006 Jan; 367(9504):23; author reply 26-7. PubMed ID: 16399140
    [No Abstract]   [Full Text] [Related]  

  • 19. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.